PrismaLung+

DEVICE2 trials

Sponsors

Vantive Health LLC

Conditions

Acute Kidney InjuryAcute Respiratory Distress SyndromeMild to Moderate Acute Respiratory Distress Syndrome

Unknown Phase

Post-Market Study of Low-flow ECCO2R Using PrismaLung+

CompletedNCT04617093

Vantive Health LLCMild to Moderate Acute Respiratory Distress Syndrome

Start: 2021-04-30End: 2024-01-10Updated: 2025-10-01

A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+

RecruitingNCT07326215

Vantive Health LLCAcute Kidney Injury, Acute Respiratory Distress Syndrome

Start: 2025-12-11End: 2027-02-28Target: 99Updated: 2026-09-16

Related Papers

A prospective clinical evaluation of new ECCO2R technology in mild to moderate ARDS patients: assessing ultra-lung-protective ventilation with PRISMALUNG.

2026-01-06